Abstract
The addition of programmed-death ligand 1 (PD-L1) inhibition with atezolizumab or durvalumab to platinum-doublet chemotherapy is the new standard treatment for extensive-stage small-cell lung cancer (ES-SCLC) as it improved survival in phase III trials, raising overall survival rate at 1 year (1-year OS) from 35% to about 50%. The vascular endothelial growth factor (VEGF) sustains angiogenesis and has immunosuppressive effects. The phase II SALUTE and the phase III FARM6PMFJM trial, the latter lead by our GOIRC group, have shown safety and provided signals of activity of bevacizumab, an anti-angiogenic agent, added to platinum doublet chemotherapy in patients with ES-SCLC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
